Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:57:44.339Z.
Calculation as of: 2026-10-06T21:57:44.339Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4efcc2f75e7b9d1a3dd193370b83b229becf15f1f7fcdbde4bbae966de3ea950
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Olema Pharmaceuticals, Inc.
Market Cap
$691.79M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$694.79M
Price/FCF Ratio
N/A
TTM Avg
30.96
3Y Avg
280.40
5Y Avg
522.37
Market Cap
$685.49M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$709.65M
Price/FCF Ratio
2.16
TTM Avg
4.81
3Y Avg
5.21
5Y Avg
6.10
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | $691.79M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $693.19M | N/A | N/A | N/A | N/A |
| Wave Life Sciences Ltd. (WVE)vs › | $693.61M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $694.79M | N/A | 30.96 | 280.40 | 522.37 |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | N/A | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $681.02M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $702.82M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.65M | 2.16 | 4.81 | 5.21 | 6.10 |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 16.60 | 12.94 | 32.63 | 32.63 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
